Brokerages expect that Cooper Companies, Inc. (The) (NYSE:COO) will announce earnings per share (EPS) of $2.57 for the current quarter, according to Zacks. Ten analysts have made estimates for Cooper Companies, Inc. (The)’s earnings, with estimates ranging from $2.51 to $2.60. Cooper Companies, Inc. (The) reported earnings of $2.30 per share in the same quarter last year, which indicates a positive year over year growth rate of 11.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, September 7th.

According to Zacks, analysts expect that Cooper Companies, Inc. (The) will report full year earnings of $9.61 per share for the current year, with EPS estimates ranging from $9.56 to $9.72. For the next fiscal year, analysts expect that the company will post earnings of $10.62 per share, with EPS estimates ranging from $10.22 to $10.77. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Cooper Companies, Inc. (The).

Cooper Companies, Inc. (The) (NYSE:COO) last issued its quarterly earnings data on Thursday, June 1st. The medical device company reported $2.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.25 by $0.25. Cooper Companies, Inc. (The) had a return on equity of 15.88% and a net margin of 16.02%. The company had revenue of $522.40 million during the quarter, compared to analysts’ expectations of $520.71 million. During the same quarter in the previous year, the company posted $2.05 earnings per share. The business’s revenue was up 8.0% on a year-over-year basis.

Several research firms have commented on COO. Oppenheimer Holdings, Inc. set a $225.00 price objective on shares of Cooper Companies, Inc. (The) and gave the company a “hold” rating in a research note on Saturday, June 3rd. Zacks Investment Research upgraded shares of Cooper Companies, Inc. (The) from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research note on Tuesday, June 6th. J P Morgan Chase & Co reiterated a “neutral” rating and issued a $206.00 price objective (up previously from $200.00) on shares of Cooper Companies, Inc. (The) in a research note on Monday, June 5th. BMO Capital Markets reiterated an “outperform” rating and issued a $255.00 price objective (up previously from $220.00) on shares of Cooper Companies, Inc. (The) in a research note on Monday, June 5th. Finally, Jefferies Group LLC increased their price objective on shares of Cooper Companies, Inc. (The) from $210.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, March 3rd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Cooper Companies, Inc. (The) has an average rating of “Buy” and a consensus target price of $230.44.

Shares of Cooper Companies, Inc. (NYSE COO) traded down 0.37% during midday trading on Wednesday, hitting $238.95. The stock had a trading volume of 586,390 shares. The stock’s 50-day moving average price is $219.67 and its 200 day moving average price is $195.56. The company has a market cap of $11.67 billion, a price-to-earnings ratio of 35.82 and a beta of 0.56. Cooper Companies, Inc. has a 52 week low of $158.73 and a 52 week high of $243.89.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Financial Market News and is owned by of Financial Market News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.financial-market-news.com/2017/06/17/brokerages-expect-cooper-companies-inc-the-coo-to-announce-2-57-eps.html.

In other news, Director Allan E. Rubenstein sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 23rd. The shares were sold at an average price of $200.00, for a total transaction of $400,000.00. Following the completion of the sale, the director now owns 5,794 shares in the company, valued at approximately $1,158,800. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director A Thomas Bender sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, March 24th. The stock was sold at an average price of $200.94, for a total transaction of $301,410.00. Following the sale, the director now owns 11,478 shares of the company’s stock, valued at approximately $2,306,389.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,292 shares of company stock valued at $14,006,145. 1.60% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of the company. YorkBridge Wealth Partners LLC raised its position in Cooper Companies, Inc. (The) by 18.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 520 shares of the medical device company’s stock worth $105,000 after buying an additional 81 shares in the last quarter. Archford Capital Strategies LLC raised its position in Cooper Companies, Inc. (The) by 116.7% in the first quarter. Archford Capital Strategies LLC now owns 674 shares of the medical device company’s stock worth $135,000 after buying an additional 363 shares in the last quarter. Penserra Capital Management LLC raised its position in Cooper Companies, Inc. (The) by 9.5% in the first quarter. Penserra Capital Management LLC now owns 782 shares of the medical device company’s stock worth $156,000 after buying an additional 68 shares in the last quarter. Pacer Advisors Inc. raised its position in Cooper Companies, Inc. (The) by 3.8% in the first quarter. Pacer Advisors Inc. now owns 848 shares of the medical device company’s stock worth $170,000 after buying an additional 31 shares in the last quarter. Finally, Dai Ichi Life Insurance Company Ltd acquired a new position in Cooper Companies, Inc. (The) during the first quarter worth $206,000. Institutional investors own 98.31% of the company’s stock.

About Cooper Companies, Inc. (The)

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Get a free copy of the Zacks research report on Cooper Companies, Inc. (The) (COO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.